tradingkey.logo

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

ReutersMar 25, 2025 11:33 AM

- Palatin Technologies Inc PTN.A:

  • PALATIN'S ORAL MC4R AGONIST PL7737 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR OBESITY DUE TO LEPTIN RECEPTOR DEFICIENCY

  • PALATIN TECHNOLOGIES INC - PLANS IND SUBMISSION FOR PL7737 IN 4Q25

  • PALATIN TECHNOLOGIES INC - EXPECTS CLINICAL DATA FOR PL7737 IN 1H26

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI